Sign Up to like & get
recommendations!
0
Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33854
Abstract: Cancer November 15, 2021 Soft tissue sarcomas (STSs) are a varied group of malignancies characterized by an evergrowing list of potential underlying genetic alterations. Although many STSs have a limited sensitivity to cytotoxic chemotherapy, identification…
read more here.
Keywords:
fusion metastatic;
arhgap23 fer;
fer fusion;
novel arhgap23 ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00872-7
Abstract: Background The third-generation tyrosine kinase inhibitor lorlatinib is approved for the treatment of ALK-positive metastatic NSCLC. CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted to evaluate the impact…
read more here.
Keywords:
healthy participants;
period;
study;
phase open ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01365-3
Abstract: Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is…
read more here.
Keywords:
recommendations management;
consensus recommendations;
management counseling;
adverse events ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2022.01.018
Abstract: BACKGROUND Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and multiple treatment options, including selective tyrosine kinase inhibitors (TKIs). Real-world evidence is insufficient…
read more here.
Keywords:
cancer;
kinase;
lorlatinib;
lung cancer ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15777
Abstract: Alectinib, an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the recommended first‐line treatment for ALK‐positive non‐small‐cell lung cancer (NSCLC) in Japan. Lorlatinib was approved as a subsequent therapeutic option after progression while receiving…
read more here.
Keywords:
lung cancer;
japanese patients;
lorlatinib;
line ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552211004698
Abstract: Introduction We report the case of a woman who developed hyperlipidemia on lorlatinib therapy found to have minimal change disease. We review therapies for cancer known to alter the lipid profile, in addition to reviewing…
read more here.
Keywords:
cancer;
lorlatinib therapy;
hyperlipidemia;
lorlatinib ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02278
Abstract: PURPOSE Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non–small-cell lung cancer (NSCLC) in the phase III CROWN trial. Here, we report post…
read more here.
Keywords:
lung cancer;
non small;
small cell;
lorlatinib ... See more keywords